Outlook Therapeutics Inc (OTLK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.44-4.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · OTLK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -85.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
OTLK — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-30
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On September 25, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price require…
Why it matters: The first U.S. sales will test whether the company can turn FDA approval into a working business.
Supportive ifThe company begins U.S. sales by December 31, 2026, as planned.
Worry ifThe company says U.S. sales will start after December 31, 2026, or reports no launch by then.
Why it matters: The company remains loss-making and needs money to fund its launch. Cash use will show how long the new funds can support it.
Worry ifThe December 18 results show cash below the June 30 level of $11.2 million, with no new funding disclosed.
Less concerning ifThe December 18 results show cash at or above $11.2 million after launch spending.
Why it matters: The next results can show whether clinics and payers are taking up the new drug.
Watch forOn December 18, the company reports U.S. sales and names payer or clinic access gains.
Also watch forOn December 18, the company reports no U.S. sales, launch delays, or access barriers.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$356 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,182 loss on $10,000 · 11.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,198 loss on $10,000 · 92.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.